共 138 条
[1]
Baecker A(2018)Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors Eur J Cancer Prev 27 205-212
[2]
Liu X(2014)The diagnosis and treatment of hepatocellular carcinoma Dtsch Arztebl Int 111 101-106
[3]
La Vecchia C(2013)Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study J Clin Oncol 31 3509-3516
[4]
Zhang ZF(2014)EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib J Clin Oncol 32 172-66
[5]
Malek NP(2017)Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet. 389 56-63
[6]
Schmidt S(2016)Regorafenib: Onkologen kritisieren Marktrücknahme Dtsch Arztebl Int 797 17-356
[7]
Huber P(2018)Cabozantinib in patients with advanced and progressing hepatocellular carcinoma N Engl J Med 379 54-675
[8]
Manns MP(2008)What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 46 349-184
[9]
Greten TF(2013)Overview of parametric survival analysis for health-economic applications Pharmacoeconomics. 31 663-1054
[10]
Llovet JM(2019)Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial J Clin Oncol 37 207-162